

# Berichrom® Protein C Berichrom PROTEIN C

**C€0197** 

Revision bar indicates update to previous version.

Reagents for the determination of protein C activity

# Intended Use

Berichrom PROTEIN C is an in vitro diagnostic reagent for the quantitative, WHO-standardized determination of protein C activity as aid to diagnosis of congenital or acquired protein C deficiencies in patients at risk for or suspected to have protein C deficiency in human sodium citrated plasma by means of automated and/or manual chromogenic methods.

# **Summary and Explanation**

Protein C is a vitamin K-dependent zymogen that has essential roles in the regulation of thrombosis and hemostasis. Physiologic activation of protein C occurs at the surface of endothelial cells, with acceleration by thrombomodulin. The activated protein C (APC), together with the cofactor protein S, limits thrombin generation by inactivation of the activated coagulation Factor V and FVIII via limited proteolysis. APC also exhibits potent cell-protective and anti-inflammatory properties<sup>1</sup>.

Congenital, heterozygous protein C deficiency occurs in about 3 % of unselected patients with a first venous thrombosis and no known malignancy, and up to 9 % of patients younger than 70 years with venous thrombosis, increasing the risk for venous thrombosis 7-fold. Homozygous protein C deficiency is often incompatible with life without anticoagulation or replacement therapy, and can present with purpura fulminans and disseminated intravascular coagulation (DIC) in the newborn period<sup>2</sup>.

Protein C activity determination is part of the thrombophilia test panel<sup>2-4</sup>. The diagnosis of protein C deficiency should be established only after other acquired causes of protein C deficiency are excluded.

Acquired protein C deficiency can be seen with warfarin or other vitamin K-antagonist therapy, vitamin K deficiency, liver disease, disseminated intravascular coagulation, renal insufficiency, proximal to acute thrombosis, and postoperatively, among others. Protein C is decreased during episodes of intravascular coagulation and sepsis<sup>3</sup>.

Protein C activity can be determined by chromogenic or coagulometric methods. The carboxylation defect of protein C induced by therapy with vitamin K antagonists results in lower activity levels observed with coagulometric methods compared to chromogenic methods<sup>2</sup>.

# Principles of the Procedure

Protein C in the patient sample is activated by a specific snake venom activator. The resulting Protein C<sub>a</sub> is assayed in a kinetic test by measuring the increase in absorbance at 405 nm. The assay is based on the following reactions:

Protein  $C_{\text{sample}} \xrightarrow{\text{Protein C Activator}} \text{Protein } C_{\text{a}}$ 

# Reagents

**Note:** Berichrom PROTEIN C can be used manually or on automated coagulation analyzers. Siemens Healthineers provides Reference Guides (Application Sheets) for several coagulation analyzers. The Reference Guides (Application Sheets) contain analyzer/assay specific handling and performance information which may differ from that provided in these Instructions for Use. In this case, the information contained in the Reference Guides (Application Sheets) supersedes the information in these Instructions for Use. Please also consult the instruction manual of the instrument manufacturer!

| Reagent                                     | Description   | Storage   | Stability                               |
|---|---|---|---|
| Berichrom® Protein C<br>Berichrom PROTEIN C |   |   |   |
| Berichrom PROTEIN C ACTIVATOR               | <ul> <li>Lyophilized reagent containing:</li> <li>extract from snake venom,         Agkistrodon contortrix         (reconstituted: ≤0.6 U/mL)</li> <li>Stabilizer</li> </ul>                      | 2–8 °C<br>May be used up to the<br>expiry date indicated on<br>the label if stored<br>unopened. | 37 °C:<br>reconstituted,<br>8 hours;    |
|   |   |   | 2–8 °C:<br>reconstituted,<br>2 weeks;   |
|   |   |   | ≤ -20 °C:<br>reconstituted,<br>4 weeks  |
| Berichrom PROTEIN C SUBSTRATE               | Lyophilized reagent containing: • p- Glu-Pro-Arg-MNA (reconstituted: 4 mmol/L)  | 2–8 °C<br>May be used up to the<br>expiry date indicated on<br>the label if stored<br>unopened. | 37 °C:<br>reconstituted,<br>1 weeks;    |
|   |   |   | 2–8 °C:<br>reconstituted,<br>6 weeks;   |
|   |   |   | ≤ -20 °C:<br>reconstituted,<br>6 months |
| Berichrom PROTEIN C ACTIVATOR DILUENT       | <ul> <li>Ready to use liquid containing:</li> <li>polyethylene glycol</li> <li>Caesium chloride</li> <li>Preservative: <ul> <li>Sodium azide (&lt; 1 g/L)</li> </ul> </li> <li>pH 8.25</li> </ul> | 2–8 °C<br>May be used up to the<br>expiry date indicated on<br>the label if stored<br>unopened. | 2–8 °C:<br>once opened,<br>6 months     |

## On-board stability

Information regarding on-board stability is specified in the Reference Guides (Application Sheets) for the different coagulation analyzers.

## **Warnings and Precautions**

- For in-vitro diagnostic use only.
- For laboratory professional use.

According to EU regulation 2017/746, any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or patient is established.

Safety data sheets (MSDS/SDS) available on siemens-healthineers.com/sds.

### Berichrom PROTEIN C ACTIVATOR

Hazardous ingredient: extract from snake venom, Agkistrodon contortrix.

May produce an allergic reaction.

#### Caution

#### Berichrom PROTEIN C ACTIVATOR

This device contains material of animal origin and should be handled as a potential carrier and transmitter of disease.

Contains sodium azide as a preservative. Sodium azide can react with copper or lead plumbing to form explosive metal azides. On disposal, flush reagents with a large volume of water to prevent the buildup of azides. Disposal into drain systems must be in compliance with prevailing regulatory requirements.

Dispose of hazardous or biologically contaminated materials according to the practices of your institution. Discard all materials in a safe and acceptable manner and in compliance with all government requirements.

Summary of Safety and Performance (SSP) is available in the European database on medical devices (see Eudamed public website: https://ec.europa.eu/tools/eudamed). In case Eudamed is not available, SSP can be delivered by Siemens Healthineers on request.

# **Preparing Reagents**

Berichrom PROTEIN C ACTIVATOR Dissolve the contents of the vial with the quantity of Berichrom

PROTEIN C ACTIVATOR DILUENT indicated on the label.

Berichrom PROTEIN C SUBSTRATE Dissolve the contents of the vial with the quantity of distilled

water indicated on the label.

Mix carefully once more before using.

# Specimen Collection and Handling

# Collecting the Specimen

To obtain the plasma, carefully mix 1 part sodium citrate solution 0.11 mol/L (3.2 %) with 9 parts venous blood, avoiding the formation of foam. Centrifuge the blood specimen immediately at  $1500 \times g$  for no less than 15 minutes at room temperature. Please refer to CLSI guideline H21-A5<sup>5</sup> for further details.

## Storing the Specimen

Stability of the samples:

 $\leq$ -20 °C 1 month 15 to 25 °C 8 hours

Thaw plasma stored at  $\leq -20$  °C within 10 minutes at 37 °C, and then perform the assay within 8 hours.

# **Procedure**

# **Materials Provided**

| REF    | Contents  |             |
|--------|---|-------------|
| OUVV15 | Berichrom <sup>®</sup> Protein C<br>Berichrom PROTEIN C     |             |
|        | Protein C Activator Berichrom PROTEIN C ACTIVATOR           | 3 × → 10 mL |
|        | Substrate Reagent<br>Berichrom PROTEIN C SUBSTRATE          | 3 × → 3 mL  |
|        | Hepes Buffer Solution Berichrom PROTEIN C ACTIVATOR DILUENT | 1 × 30 mL   |
| OUVV17 | Berichrom <sup>®</sup> Protein C<br>Berichrom PROTEIN C     |             |
|        | Protein C Activator Berichrom PROTEIN C ACTIVATOR           | 4 × → 5 mL  |
|        | Substrate Reagent<br>Berichrom PROTEIN C SUBSTRATE          | 2 × → 3 mL  |
|        | Hepes Buffer Solution Berichrom PROTEIN C ACTIVATOR DILUENT | 1 × 30 mL   |

# Materials Required but not Provided

| Item  | Description  |
|---|--|
| REF ORKE41                                    | CONTROL N, Control Plasma N  |
| REF OUPZ17                                    | CONTROL P, Control Plasma P  |
| REF B4234-25 REF B4265-37                     | OV BUFFER, Dade® Owren's Veronal Buffer, or CA SYSTEM BUFFER, Dade® CA System Buffer, or Isotonic Saline Solution  |
| REF ORKL17                                    | STANDARD PLASMA, Standard Human Plasma   |
| _   | Acetic acid 20 % (only for two-point method)   |
| Coagulation analyzers <sup>a</sup> , such as: | <ul> <li>Atellica® COAG 360 System</li> <li>BCS® XP System</li> <li>SYSMEX CA-500/CA-600 series</li> <li>SYSMEX CA-1500 System</li> <li>SYSMEX CS-2000i/CS-2100i System</li> <li>SYSMEX CS-2500 System</li> <li>SYSMEX CS-5100 System</li> </ul> |

<sup>&</sup>lt;sup>a</sup> Availability of analyzers may vary by country.

Please note that the applications on other analyzers can be validated by the instrument manufacturer in accordance with the requirements of the REGULATION (EU) 2017/746 under their responsibility as long as the intended purpose and performance are not modified.

# **Test Procedure**

# Manual

Semi-micro test:

cuvette: 1 cm path length

wavelength: 405 nm test temperature:  $37 \,^{\circ}\text{C}$ 

Pre-warm the Berichrom PROTEIN C ACTIVATOR and Berichrom PROTEIN C SUBSTRATE as well as the plastic cuvettes/tubes to 37 °C prior to the test.

#### A. Pipetting scheme for the kinetic method

|  | Semi-micro test |  |
|--|-----------------|--|
| Plasma sample                                    | 100 μL          |  |
| Berichrom PROTEIN C ACTIVATOR                    | 1 000 μL        |  |
| Mix and incubate for exactly 5 minutes at 37 °C. |                 |  |
| Substrate Reagent                                | 200 μL          |  |
| Min and determine AA (min                        |                 |  |

Mix and determine ΔA 405 nm/min

After approx. 15 seconds, read the absorbance and start the stopwatch simultaneously. After exactly 60 and 120 seconds, read the absorbance again, calculate the respective  $\Delta A/min$  values by subtraction, and then calculate the mean value of the two  $\Delta A$  readings.

#### Evaluation, kinetic method

Calculation of the factor:

$$F_{L} = \frac{Assigned \ value \ (\% \ of \ Norm)_{reference \ plasma}}{\Delta A/min_{reference \ plasma}}$$

Multiply the  $\Delta A$ /min of the samples by the resulting factor; the protein C content is obtained in % of Norm

Protein  $C_{sample}$  (% of Norm) =  $F_L \times \Delta A/min_{sample}$ 

#### B. Pipetting scheme for the two-point method

|   | Sample   | Sample blank |  |
|---|----------|--------------|--|
| Plasma sample   | 100 μL   | 100 μL       |  |
| Berichrom PROTEIN C ACTIVATOR   | 1000 μL  | -            |  |
| Isotonic saline solution  | _        | 1 000 μL     |  |
| Mix and incubate for exactly 5 minutes at 37 °C.                                      |          |              |  |
| Substrate Reagent   | 200 μL   | 200 μL       |  |
| Mix immediately and start the stopwatch simultaneously. After exactly 5 minutes, add: |          |              |  |
| Acetic acid 20 %  | 1 000 μL | 1 000 μL     |  |
| Mix immediately and read the absorbance against the blank within 60 minutes.          |          |              |  |

#### Evaluation, two-point method

Calculation of the factor:

$$F_{L} = \frac{Assigned \ value \ (\% \ of \ Norm)_{reference \ plasma}}{A_{reference \ plasma}}$$

Multiply the absorbance of the sample by the resulting factor.

Protein  $C_{sample}$  (% of Norm) =  $F_L \times A_{sample}$ 

#### Notes

- 1. Doubling or halving of volumes used in the test mixtures has no effect on the calculation or laboratoryinternal calculation factor.
- 2. F<sub>L</sub> is a calculating factor established within the laboratory and needs to be determined only once in an assay series. This method of evaluation is basically equivalent to an evaluation via a reference curve.
- 3. The laboratory-internal factor F<sub>L</sub> and/or reference curve must be re-determined for each change of device and for each new lot of Berichrom PROTEIN C.

# **Internal Quality Control**

Normal range: CONTROL N
Pathological range: CONTROL P

Two controls should be measured with each calibration and at least every 8 hours during each testing day (one in the normal range and one in the pathological range). The controls should be processed just like the samples. Each laboratory should determine its own quality control range, either by means of the target values and ranges provided by the manufacturer of the controls or by means of its own confidence range established in the laboratory. If the measured control value lies outside the confidence range previously established, then the reagents, the laboratory-internal factor F<sub>L</sub> and/or the calibration curve and the coagulation analyzer should be examined. Do not release patient results until the cause of deviation has been identified and corrected.

# Limitations

False low protein C activity may be obtained in patients being treated with aprotinin6.

Hemolyzed samples are not suitable for protein C determination.

Some very rare protein C type IIb defects on the substrate binding sites may yield results within the reference range<sup>3</sup>.

Siemens Healthineers has validated use of these reagents on various analyzers to optimize product performance and meet product specifications. Please note that the applications on other analyzers can be validated by the instrument manufacturer in accordance with the requirements of the REGULATION (EU) 2017/746 under their responsibility as long as the intended purpose and performance are not modified. User defined modifications are not supported by Siemens Healthineers as they may affect performance of the system and assay results. It is the responsibility of the user to validate modifications to these instructions or use of the reagents on analyzers other than those included in Siemens Healthineers Application Sheets or these Instructions for Use.

Results of this test should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

# **Expected Values**

70 to 140 % of Norm7

Expected values for healthy individuals vary from laboratory to laboratory depending on the technique used; therefore, each laboratory must determine or verify its own expected values for its particular patient population based on the technique and instrumentation.

# **Performance Characteristics**

# **Measuring Range**

The measuring range extends from 10 to 150 % of Norm.

The measuring range depends on the individual application of the assay due to instrument related conditions. Application specific performance data is listed in the respective Reference Guides of the instruments.

#### **Precision**

For protein C values in the reference range, the coefficient of variation from day to day lies at 1.9 %. For pathological values, the coefficient of variation from day to day lies at 0.4 %.

Other system specific results are given in the respective Reference Guides (Application Sheets).

The reproducibility was assessed by Siemens Healthineers for Protein C with Berichrom **PROTEIN C** based on proficiency testing information in 2019/2020. The overall reproducibility median CV% was found to be < 7 % including lot, instrument, laboratory and operator variability factors.

## **Method Comparison**

In a comparison of Berichrom PROTEIN C with immunochemical and other chromogenic methods, the correlation coefficients were equal or better then 0.90<sup>8</sup>.

# **Technical Assistance**

For customer support, contact your local technical support provider or distributor. siemens-healthineers.com

# **Current Version of Application Sheets**

Berichrom PROTEIN C can be used in combination with various automated coagulation analyzers. Siemens Healthineers provides Reference Guides/Application Sheets for the coagulation analyzers listed in section "Materials Required but not Provided", page 4 under the dedicated link below: siemens-healthineers.com/rg

As Siemens Healthineers continuously monitors the product performance and safety, the users are required to ensure that they work with the correct revision of the instructions for the product lots in use. Please periodically review the availability of new electronic labeling revisions to ensure safe use of the product.

The IFU version number is visible on each product box label. Siemens Healthineers ensures that all products lots bearing the same IFU version number are compatible with the electronic labeling provided via siemens-healthineers.com/eIFU.

# References

- 1. Dinarvand P, Moser K. Protein C Deficiency. Arch Pathol Lab Med. 2019 Jan 31.
- 2. Khor B, Van Cott EM. Laboratory tests for protein C deficiency. Am J Hematol 2010;85(6):440-2.
- 3. Marlar RA, Gausman JN. Laboratory testing issues for protein C, protein S, and antithrombin. Int J Lab Hematol. 2014;36:289-95.
- Kottke-Marchant K, Comp P. Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. Arch Pathol Lab Med. 2002;126(11):1337-48.
- 5. CLSI. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays. Approved Guideline Fifth Edition. CLSI document **H21-A5** [ISBN 1-56238-657-3]. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA, 2008.
- 6. Espana F, Estelles A, Griffin JH, et al. Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thromb Res. 1989; 56: 751-6.
- 7. Kraus M. Protein C, protein S, factor V Leiden. In: Thomas L, ed. Clinical Laboratory Diagnostics. Frankfurt: TH-Books Verlagsgesellschaft. 1998: 621-5.
- 8. Sturk A, Morrien-Salomons WM, Huisman MV, et al. Analytical and clinical evaluation of commercial protein C assays. Clin Chim Acta. 1987; 165: 263-70.

# **Definition of Symbols**

The following symbols may appear on the product labeling:

| <b>(2)</b>     | Do not reuse  | 2<             | Use By                                |
|----------------|---|----------------|---------------------------------------|
| LOT            | Batch Code  | REF            | Catalogue Number                      |
| $\triangle$    | Caution   | ***            | Manufacturer                          |
| EC REP         | Authorized representative in the<br>European Community                                      | $\Sigma$       | Contains sufficient for <n> tests</n> |
| <b>₩</b>       | Biological Risks  | IVD            | In Vitro Diagnostic Medical<br>Device |
| 1              | Temperature Limitation  | $\bigcap$ i    | Consult instruction for Use           |
| NON<br>STERILE | Non-sterile   | C€             | CE marking of conformity              |
| C€0197         | CE marking of conformity with notified body ID number.<br>Notified body ID number can vary. | CONTENTS       | Contents                              |
| <b>→</b>       | Reconstitution volume   | LEVEL          | Level                                 |
| 类              | Keep away from sunlight and heat  | WARNING        | Warning                               |
| DANGER         | Danger  | RxOnly         | Prescription device (US only)         |
| UDI            | Device Identification (UDI) barcode   | REACH xx/xx/xx | REACH Authorization Number            |

# **Legal Information**

Atellica, BCS, Berichrom and Dade are trademarks of Siemens Healthineers. SYSMEX is a trademark of SYSMEX CORPORATION.

All other trademarks are the property of their respective owners.

© Siemens Healthineers, 2010–2021. All rights reserved.

## Siemens Healthineers Headquarters

Siemens Healthcare GmbH Henkestraße 127 91052 Erlangen Germany Phone: +49 9131 84-0

Phone: +49 9131 84-0 siemens-healthineers.com

#### \*\*\*

## Siemens Healthcare Diagnostics Products GmbH

Emil-von-Behring-Str. 76 35041 Marburg Germany siemens-healthineers.com